Evangelos Terpos to Double-Blind Method
This is a "connection" page, showing publications Evangelos Terpos has written about Double-Blind Method.
Connection Strength
0.121
-
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv. 2018 11 13; 2(21):2837-2847.
Score: 0.083
-
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 03; 19(3):370-381.
Score: 0.020
-
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br J Haematol. 2017 Mar; 176(5):783-795.
Score: 0.018